What is Big Think?  

We are Big Idea Hunters…

We live in a time of information abundance, which far too many of us see as information overload. With the sum total of human knowledge, past and present, at our fingertips, we’re faced with a crisis of attention: which ideas should we engage with, and why? Big Think is an evolving roadmap to the best thinking on the planet — the ideas that can help you think flexibly and act decisively in a multivariate world.

A word about Big Ideas and Themes — The architecture of Big Think

Big ideas are lenses for envisioning the future. Every article and video on bigthink.com and on our learning platforms is based on an emerging “big idea” that is significant, widely relevant, and actionable. We’re sifting the noise for the questions and insights that have the power to change all of our lives, for decades to come. For example, reverse-engineering is a big idea in that the concept is increasingly useful across multiple disciplines, from education to nanotechnology.

Themes are the seven broad umbrellas under which we organize the hundreds of big ideas that populate Big Think. They include New World Order, Earth and Beyond, 21st Century Living, Going Mental, Extreme Biology, Power and Influence, and Inventing the Future.

Big Think Features:

12,000+ Expert Videos

1

Browse videos featuring experts across a wide range of disciplines, from personal health to business leadership to neuroscience.

Watch videos

World Renowned Bloggers

2

Big Think’s contributors offer expert analysis of the big ideas behind the news.

Go to blogs

Big Think Edge

3

Big Think’s Edge learning platform for career mentorship and professional development provides engaging and actionable courses delivered by the people who are shaping our future.

Find out more
Close

An Introduction to Breakthroughs: Alzheimer's Disease

November 17, 2010, 2:36 PM
Bumper_screengrab

Our society is faced with a disturbing reality: One in eight people aged 65 and older has Alzheimer’s—a disease that currently has no cure.  Annual costs associated with the disease exceed $172 billion, and the number of unpaid caregivers in the U.S.—friends and family of someone stricken with Alzheimer's disease—is currently estimated to be 10.9 million people.

In October, Big Think hosted a panel discussion highlighting cutting-edge Alzheimer's disease research as part of our Breakthroughs series, made possible by Pfizer. This top-level conversation featured back-and-forth exchanges between luminaries in the field, including:

Gandy

Dr. Samuel Gandy, Mount Sinai Professor of Alzheimer's Disease Research, Professor of Neurology and Psychiatry, Associate Director of the Mount Sinai Alzheimer's Disease Research Center in New York City.

 

Guarente

Dr. Leonard Guarente, Director of Glenn Lab for Science of Aging at MIT.  Dr. Guarente is best known for his research on longevity and specifically for uncovering the gene in yeast that governs the organism's life span.

 

Troncoso 2

Dr. Juan Troncoso, Director of the Brain Resource Center at Johns Hopkins University School of Medicine.  Dr. Troncoso’s research interests focus on the neuropathology of normal aging and the pathology, pathogenesis and therapy of neurodegenerative disorders, such as Alzheimer’s disease, Frontotemporal Dementia, Parkinson’s disease and Huntington’s disease. 

Arancio

Dr. Ottavio Arancio, Professor of Pathology & Cell Biology at the Columbia University Medical Center.  During the past decade he has pioneered the field of mechanisms of synaptic dysfunction in Alzheimer’s disease.

 

Meryl

The panel was moderated by Meryl Comer, President of the Geoffrey Beene Foundation Alzheimer’s Initiative.  She has spent the past 16 years as the at-home caregiver for her husband who was diagnosed with early-onset Alzheimer’s at the age of 58.

 

Over the next four weeks, Big Think will look at the latest thinking and research about the causes and progression of Alzheimer's disease, using information from this panel discussion to analyze what the latest research is revealing about predisposition to the disease and what might be done to prevent it.

Produced by Big Think and made possible by Pfizer, Breakthroughs is a three-part series that focuses on leading-edge medical research. Two additional installments—one dedicated to autism and another to oncology—will launch in early 2011.

The views expressed here are solely those of the participants, and do not represent the views of Big Think or its sponsors.

 

An Introduction to Breakthr...

Newsletter: Share: